Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo [Phase 2]

View source ↗

Summary

This Phase 2 trial is evaluating the safety and effectiveness of neoadjuvant TACE combined with atezolizumab and bevacizumab in patients with high-risk, resecta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Resectable Hepatocellular Carcinoma With High Risk of Recurrence | Phase 2 | Status: RECRUITING